Stocktoria
ORAMED PHARMACEUTICALS INC. ORMP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2002-04-01
ORAMED PHARMACEUTICALS INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 0.7% | — | — | — | — |
| Operating margin | -754.4% | — | -1176.8% | -1502.0% | -896.2% |
| Net margin | 3202.5% | — | 379.7% | -1352.6% | -850.5% |
| FCF margin | -457.7% | — | -787.2% | -1051.2% | -797.5% |
| Return on assets | 27.7% | -12.3% | 2.3% | -22.6% | -18.0% |
| Return on equity | 32.1% | -13.0% | 3.1% | -24.1% | -19.7% |
| Debt / equity | — | — | — | 0.00× | 0.11× |
| Current ratio | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 |
| Revenue growth | — | — | -50.4% | 0.0% | -0.3% |
Source: SEC EDGAR filings · CIK 0001176309 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.